The Cure She Was Already Building: When a Daughter’s Research Became Her Father’s Lifeline
For years, it was just work.
Long hours. Complex data. Clinical trials that stretched across time zones and timelines. The kind of work that rarely makes headlines—but quietly changes lives.
At Pfizer, one physician-turned-executive dedicated her career to studying a rare and often overlooked heart condition: Transthyretin Amyloid Cardiomyopathy.
It’s a disease most people have never heard of. But for those affected, it’s devastating.
ATTR-CM occurs when a protein called transthyretin becomes unstable and misfolds. Instead of circulating normally, it builds up in the heart. Over time, that buildup stiffens the heart muscle, leading to heart failure. It can be hereditary—or it can appear later in life without warning.
For decades, there were few effective treatment options.
That’s what made the work so important.
Brenda Cooperstone had trained as a pediatrician, but her path eventually led her into pharmaceutical development—specifically in the field of rare diseases.
Her role at Pfizer placed her at the forefront of research into ATTR-CM, where she helped lead development efforts for a drug designed to stabilize the transthyretin protein and prevent it from misfolding.
That drug would eventually become known as tafamidis—marketed as Vyndaqel and Vyndamax.
But like all breakthroughs in medicine, it didn’t happen overnight.
Years of research.
Years of trials.
Years of waiting.
And during that time, life outside the lab continued.
In her father’s early 80s, subtle symptoms began to appear.
Fatigue.
Shortness of breath.
A gradual decline that could easily be attributed to aging.
But Brenda had spent over a decade studying ATTR-CM.
She knew how quietly it could present.
How often it went undiagnosed.
How easily it could be missed.
And something didn’t feel right.
Encouraging a parent to undergo testing—especially for a rare condition—wasn’t simple. But eventually, he agreed.
In 2018, the diagnosis was confirmed.
He had ATTR-CM.
The same disease she had been studying for years.
Historically, a diagnosis like that came with limited options.
But this moment was different.
Because after years of research and clinical trials, tafamidis was reaching a turning point. It would go on to become the first FDA-approved treatment specifically for ATTR-CM, shown to reduce mortality and cardiovascular-related hospitalizations.
Suddenly, the work Brenda had dedicated her career to wasn’t just helping patients in the abstract.
It was helping her father.
Because she recognized the signs early…
Because she understood the disease…
Because she was part of the team bringing a treatment forward…
Her father was able to receive a diagnosis sooner—and begin treatment at a stage where it could make a meaningful difference.
There are countless researchers working behind the scenes in medicine—people whose work may never intersect directly with their own lives.
But sometimes… it does.
In this case, years of dedication, expertise, and persistence aligned in a way no one could have predicted.
A daughter studying a rare disease.
A father unknowingly developing it.
A treatment arriving just in time.
Not in a lab.
Not in a clinical trial.
But at a family level.
🔗 Explore more stories at https://twistoffateradio.com
🎙️ For voiceover work, visit https://clarkvoservices.com